In terms of therapeutic applications, inhibition of MAGED2 could target the oncoproteins Gαs and HIF-1α specifically in hypoxic tumors, and its activation may enhance HIF-1α induction in kidney disease. This evidence concerns the gene HIF1A and kidney disorder.